Search Results - "Sievers, Quinlan"

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide by Jan, Max, Scarfò, Irene, Larson, Rebecca C, Walker, Amanda, Schmidts, Andrea, Guirguis, Andrew A, Gasser, Jessica A, Słabicki, Mikołaj, Bouffard, Amanda A, Castano, Ana P, Kann, Michael C, Cabral, Maria L, Tepper, Alexander, Grinshpun, Daniel E, Sperling, Adam S, Kyung, Taeyoon, Sievers, Quinlan L, Birnbaum, Michael E, Maus, Marcela V, Ebert, Benjamin L

“…Cell-based therapies are emerging as effective agents against cancer and other diseases. As autonomous "living drugs," these therapies lack precise control…”
Get more information

Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN by Sievers, Quinlan L, Petzold, Georg, Bunker, Richard D, Renneville, Aline, Słabicki, Mikołaj, Liddicoat, Brian J, Abdulrahman, Wassim, Mikkelsen, Tarjei, Ebert, Benjamin L, Thomä, Nicolas H

“…The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros…”
Get full text

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K by Słabicki, Mikołaj, Kozicka, Zuzanna, Petzold, Georg, Li, Yen-Der, Manojkumar, Manisha, Bunker, Richard D., Donovan, Katherine A., Sievers, Quinlan L., Koeppel, Jonas, Suchyta, Dakota, Sperling, Adam S., Fink, Emma C., Gasser, Jessica A., Wang, Li R., Corsello, Steven M., Sellar, Rob S., Jan, Max, Gillingham, Dennis, Scholl, Claudia, Fröhling, Stefan, Golub, Todd R., Fischer, Eric S., Thomä, Nicolas H., Ebert, Benjamin L.

“…Molecular glue compounds induce protein–protein interactions that, in the context of a ubiquitin ligase, lead to protein degradation 1 . Unlike traditional…”
Get full text

Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia by Tothova, Zuzana, Krill-Burger, John M., Popova, Katerina D., Landers, Catherine C., Sievers, Quinlan L., Yudovich, David, Belizaire, Roger, Aster, Jon C., Morgan, Elizabeth A., Tsherniak, Aviad, Ebert, Benjamin L.

“…Hematologic malignancies are driven by combinations of genetic lesions that have been difficult to model in human cells. We used CRISPR/Cas9 genome engineering…”
Get full text

SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia by Wang, Lili, Lawrence, Michael S, Wan, Youzhong, Stojanov, Petar, Sougnez, Carrie, Stevenson, Kristen, Werner, Lillian, Sivachenko, Andrey, DeLuca, David S, Zhang, Li, Zhang, Wandi, Vartanov, Alexander R, Fernandes, Stacey M, Goldstein, Natalie R, Folco, Eric G, Cibulskis, Kristian, Tesar, Bethany, Sievers, Quinlan L, Shefler, Erica, Gabriel, Stacey, Hacohen, Nir, Reed, Robin, Meyerson, Matthew, Golub, Todd R, Lander, Eric S, Neuberg, Donna, Brown, Jennifer R, Getz, Gad, Wu, Catherine J

“…CLL is a heterogeneous disease with a variable clinical course and response to therapy. New genetic lesions have been noted in subgroups of patients through…”
Get full text

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs by Sperling, Adam S., Burgess, Michael, Keshishian, Hasmik, Gasser, Jessica A., Bhatt, Shruti, Jan, Max, Słabicki, Mikołaj, Sellar, Rob S., Fink, Emma C., Miller, Peter G., Liddicoat, Brian J., Sievers, Quinlan L., Sharma, Rohan, Adams, Dylan N., Olesinski, Elyse A., Fulciniti, Mariateresa, Udeshi, Namrata D., Kuhn, Eric, Letai, Anthony, Munshi, Nikhil C., Carr, Steven A., Ebert, Benjamin L.

“…Pharmacologic agents that modulate ubiquitin ligase activity to induce protein degradation are a major new class of therapeutic agents, active in a number of…”
Get full text

Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins by Shirasaki, Ryosuke, Matthews, Geoffrey M., Gandolfi, Sara, de Matos Simoes, Ricardo, Buckley, Dennis L., Raja Vora, Joseline, Sievers, Quinlan L., Brüggenthies, Johanna B., Dashevsky, Olga, Poarch, Haley, Tang, Huihui, Bariteau, Megan A., Sheffer, Michal, Hu, Yiguo, Downey-Kopyscinski, Sondra L., Hengeveld, Paul J., Glassner, Brian J., Dhimolea, Eugen, Ott, Christopher J., Zhang, Tinghu, Kwiatkowski, Nicholas P., Laubach, Jacob P., Schlossman, Robert L., Richardson, Paul G., Culhane, Aedin C., Groen, Richard W.J., Fischer, Eric S., Vazquez, Francisca, Tsherniak, Aviad, Hahn, William C., Levy, Joan, Auclair, Daniel, Licht, Jonathan D., Keats, Jonathan J., Boise, Lawrence H., Ebert, Benjamin L., Bradner, James E., Gray, Nathanael S., Mitsiades, Constantine S.

“…Heterobifunctional proteolysis-targeting chimeric compounds leverage the activity of E3 ligases to induce degradation of target oncoproteins and exhibit potent…”
Get full text

Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL by Wang, Lili, Shalek, Alex K., Lawrence, Mike, Ding, Ruihua, Gaublomme, Jellert T., Pochet, Nathalie, Stojanov, Petar, Sougnez, Carrie, Shukla, Sachet A., Stevenson, Kristen E., Zhang, Wandi, Wong, Jessica, Sievers, Quinlan L., MacDonald, Bryan T., Vartanov, Alexander R., Goldstein, Natalie R., Neuberg, Donna, He, Xi, Lander, Eric, Hacohen, Nir, Regev, Aviv, Getz, Gad, Brown, Jennifer R., Park, Hongkun, Wu, Catherine J.

“…One major goal of cancer genome sequencing is to identify key genes and pathways that drive tumor pathogenesis. Although many studies have identified candidate…”
Get full text

Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity by Sievers, Quinlan L., Gasser, Jessica A., Cowley, Glenn S., Fischer, Eric S., Ebert, Benjamin L.

“…Lenalidomide mediates the ubiquitination and degradation of Ikaros family zinc finger protein 1 (IKZF1), IKZF3, and casein kinase 1α (CK1α) by facilitating…”
Get full text

Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells by Burkhardt, Ute E, Hainz, Ursula, Stevenson, Kristen, Goldstein, Natalie R, Pasek, Mildred, Naito, Masayasu, Wu, Di, Ho, Vincent T, Alonso, Anselmo, Hammond, Naa Norkor, Wong, Jessica, Sievers, Quinlan L, Brusic, Ana, McDonough, Sean M, Zeng, Wanyong, Perrin, Ann, Brown, Jennifer R, Canning, Christine M, Koreth, John, Cutler, Corey, Armand, Philippe, Neuberg, Donna, Lee, Jeng-Shin, Antin, Joseph H, Mulligan, Richard C, Sasada, Tetsuro, Ritz, Jerome, Soiffer, Robert J, Dranoff, Glenn, Alyea, Edwin P, Wu, Catherine J

“…Patients with advanced hematologic malignancies remain at risk for relapse following reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell…”
Get full text

Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias by de Matos Simoes, Ricardo, Shirasaki, Ryosuke, Downey-Kopyscinski, Sondra L, Matthews, Geoffrey M, Barwick, Benjamin G, Gupta, Vikas A, Dupéré-Richer, Daphné, Yamano, Shizuka, Hu, Yiguo, Sheffer, Michal, Dhimolea, Eugen, Dashevsky, Olga, Gandolfi, Sara, Ishiguro, Kazuya, Meyers, Robin M, Bryan, Jordan G, Dharia, Neekesh V, Hengeveld, Paul J, Brüggenthies, Johanna B, Tang, Huihui, Aguirre, Andrew J, Sievers, Quinlan L, Ebert, Benjamin L, Glassner, Brian J, Ott, Christopher J, Bradner, James E, Kwiatkowski, Nicholas P, Auclair, Daniel, Levy, Joan, Keats, Jonathan J, Groen, Richard W J, Gray, Nathanael S, Culhane, Aedin C, McFarland, James M, Dempster, Joshua M, Licht, Jonathan D, Boise, Lawrence H, Hahn, William C, Vazquez, Francisca, Tsherniak, Aviad, Mitsiades, Constantine S

“…Clinical progress in multiple myeloma (MM), an incurable plasma cell (PC) neoplasia, has been driven by therapies that have limited applications beyond MM/PC…”
Get full text

Using an in-Vivo Degron-Based Approach to Interrogate Dependencies of Serially Acquired Mutations - Including DNMT3a-R882 and NPM1c - in Acute Myeloid Leukemia by Guirguis, Andrew A, Tepper, Alexander, Jan, Max, Sievers, Quinlan, Ebert, Benjamin L.

“…•While a number of targeted therapies have recently become available in the treatment of acute myeloid leukemia (AML), it remains to be determined whether…”
Get full text

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127 by Montoya, Skye, Bourcier, Jessie, Noviski, Mark, Lu, Hao, Thompson, Meghan C, Chirino, Alexandra, Jahn, Jacob, Sondhi, Anya K, Gajewski, Stefan, Tan, Ying Siow May, Yung, Stephanie, Urban, Aleksandra, Wang, Eric, Han, Cuijuan, Mi, Xiaoli, Kim, Won Jun, Sievers, Quinlan, Auger, Paul, Bousquet, Hugo, Brathaban, Nivetha, Bravo, Brandon, Gessner, Melissa, Guiducci, Cristiana, Iuliano, James N, Kane, Tim, Mukerji, Ratul, Reddy, Panga Jaipal, Powers, Janine, Sanchez Garcia de Los Rios, Mateo, Ye, Jordan, Barrientos Risso, Carla, Tsai, Daniel, Pardo, Gabriel, Notti, Ryan Q, Pardo, Alejandro, Affer, Maurizio, Nawaratne, Vindhya, Totiger, Tulasigeri M, Pena-Velasquez, Camila, Rhodes, Joanna M, Zelenetz, Andrew D, Alencar, Alvaro, Roeker, Lindsey E, Mehta, Sanjoy, Garippa, Ralph, Linley, Adam, Soni, Rajesh Kumar, Skånland, Sigrid S, Brown, Robert J, Mato, Anthony R, Hansen, Gwenn M, Abdel-Wahab, Omar, Taylor, Justin

“…Increasing use of covalent and noncovalent inhibitors of Bruton's tyrosine kinase (BTK) has elucidated a series of acquired drug-resistant BTK mutations in…”
Get full text

UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability by Tsai, Jonathan M, Aguirre, Jacob D, Li, Yen-Der, Brown, Jared, Focht, Vivian, Kater, Lukas, Kempf, Georg, Sandoval, Brittany, Schmitt, Stefan, Rutter, Justine C, Galli, Pius, Sandate, Colby R, Cutler, Jevon A, Zou, Charles, Donovan, Katherine A, Lumpkin, Ryan J, Cavadini, Simone, Park, Paul M C, Sievers, Quinlan, Hatton, Charlie, Ener, Elizabeth, Regalado, Brandon D, Sperling, Micah T, Słabicki, Mikołaj, Kim, Jeonghyeon, Zon, Rebecca, Zhang, Zinan, Miller, Peter G, Belizaire, Roger, Sperling, Adam S, Fischer, Eric S, Irizarry, Rafael, Armstrong, Scott A, Thomä, Nicolas H, Ebert, Benjamin L

“…Nuclear hormone receptors (NRs) are ligand-binding transcription factors that are widely targeted therapeutically. Agonist binding triggers NR activation and…”
Get full text

UBR5 Is a Hect E3 Ubiquitin Ligase That Regulates Chromatin Bound Nuclear Hormone Receptor Stability by Tsai, Jonathan M, Aguirre, Jacob D, Brown, Jared, Focht, Vivian, Li, Yen-Der, Kempf, Georg, Kater, Lukas, Galli, Pius, Cavadini, Simone, Sandoval, Brittany E, Zou, Charles, Rutter, Justine, Donovan, Katherine, Sievers, Quinlan, Park, Paul, Cutler, Jevon A., Hatton, Charlie, Ener, Elizabeth, Sperling, Micah T, Slabicki, Mikolaj, Miller, Peter G., Belizaire, Roger, Sperling, Adam S., Armstrong, Scott A., Fischer, Eric S., Thomä, Nicolas, Ebert, Benjamin L.

Get full text

Abstract PL02-03: The zinc-finger degrome by Sievers, Quinlan L., Petzold, Georg, Bunker, Richard D., Renneville, Aline, Liddicoat, Brian, Abdulrahman, Wassim, Mikkelsen, Tarjei, Ebert, Benjamin L., Thoma, Nicolas H.

“…Abstract The small molecule drugs thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of Ikaros (IKZF1) and…”
Get full text

Genome-Scale Screen Reveals Genes Required for Lenalidomide-Mediated Degradation of Aiolos By CRL4-CRBN by Sievers, Quinlan, Gasser, Jessica, Cowley, Glenn, Doench, John G, Fischer, Eric, Ebert, Benjamin L

“…Lenalidomide exerts its therapeutic effects in the malignancy multiple myeloma by facilitating the degradation of the transcription factors Ikaros (IKZF1) and…”
Get full text

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors by Jan, Max, Castano, Ana, Walker, Amanda, Guirguis, Andrew A, Gasser, Jessica A, Bouffard, Amanda A, Slabicki, Mikolaj, Tepper, Alexander, Grinshpun, Daniel E, Kyung, Taeyoon, Sievers, Quinlan, Birnbaum, Michael E, Maus, Marcela V, Ebert, Benjamin L.

“…Cell-based therapies are emerging as potent agents against cancer and other diseases, but are uniquely uncontrolled “living drugs”. For example, chimeric…”
Get full text

Generation of Models of Human Hematologic Malignancies Using CRISPR Genome Engineering by Tothova, Zuzana, Krill-Burger, John M, Popova, Katerina D, Sievers, Quinlan, Yudovich, David, Belizaire, Roger, Aster, Jon C., Morgan, Elizabeth A., Tsherniak, Aviad, Ebert, Benjamin L

“…Hematopoietic malignancies are genetically complex diseases in which the serial acquisition of somatic mutations results in clonal diversity with distinct…”
Get full text

Abstract LB-118: Characterization of lineage vs. context-dependent essential genes in multiple myeloma using CRISPR-Cas9 genome editing by Matthews, Geoffrey M., Simoes, Ricardo de Matos, Hu, Yiguo, Sheffer, Michal, Dashevsky, Olga, Dhimolea, Eugen, Hengeveld, Paul J., Glassner, Brian J., Gandolfi, Sara, Bariteau, Megan A., Sievers, Quinlan, Ebert, Benjamin L., Vazquez, Franciska, Culhane, Aedin, Mitsiades, Constantine S.

“…Abstract Multiple Myeloma (MM) remains incurable in part due to an incomplete understanding of the genes critically responsible for MM cell survival and…”
Get full text